demonstrated that LRP1 inhibition alleviated tumorigenesis in leukemia models by inhibiting the Notch signaling pathway.[6] By contrast, reduced LRP1 expression was shown to enhance the aggressiveness and invasiveness of HCCs by increasing the expression and bioactivity of matrix metalloproteinase 9 (MMP9), which was inconsistent with the results observed in epithelial ovarian cancer cells and breast cancer.[5, 7] Thus, the underlying mechanisms by which LRP1 is involved in HCC pathogenesis require further investigation. Here, MMP9 is linked to breast cancer.